Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma: John Kuruvilla, MD

This past weekend in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, John Kuruvilla, MD, presented results of the phase 3 KEYNOTE-204 trial, reporting that pembrolizumab significantly increased progression-free survival compared with brentuximab vedotin in patients with relapsed/refractory classic Hodgkin lymphoma. In this interview with i3 Health, Dr. Kuruvilla, an Associate Professor of Medicine at the University of Toronto, discusses the challenges of treatin...
Continue reading

Daratumumab Increases Listeria Susceptibility

Patients with multiple myeloma who are receiving daratumumab (Darzalex®, Janssen) have an increased susceptibility to listeriosis, a potentially deadly infection by Listeria monocytogenes, a gram-positive bacterium to which individuals with weakened immune systems are susceptible. Daratumumab, a CD38 monoclonal antibody, is effective against multiple myeloma because CD38 is strongly expressed in multiple myeloma cells. However, activated macrophages also express CD38. It seems to be an important...
Continue reading

Prophylactic Cranial Irradiation for Locally Advanced NSCLC

Patients with locally advanced non-small cell lung cancer (NSCLC) are at high risk for developing brain metastases. In other cancers that have a propensity to metastasize to the brain, including small cell lung cancer, a treatment called prophylactic cranial irradiation (PCI) is used in order to prevent brain metastases. Now, a phase 3 clinical trial reports that PCI also decreases a patient's chances of developing brain metastasis in NSCLC. In this study, which was published in JAMA Oncology, 3...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.